Clinical Trial Update: A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BL-B01D1 in combination with lenvatinib for advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BL-B01D1
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING